Meeting
2024 ASCO Genitourinary Cancers Symposium
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcome (PRO) measures.
Authors
Stephen J. Freedland
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Durham VA Medical Center, Los Angeles, CA
Stephen J. Freedland , John Mulhall , Martin Gleave , Ugo De Giorgi , Fred Saad , Antti Rannikko , Jasmina I. Ivanova , Anchen Nasr , Arlene Reisman , Arijit Ganguli , Pavol Kral , Neal D. Shore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Clinical Trial Registration Number
NCT02319837
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 313)
DOI
10.1200/JCO.2024.42.4_suppl.313
Abstract #
313
Poster Bd #
N4
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: Post-hoc analysis of PROSPER by prior therapy.
First Author: Ugo De Giorgi
Poster
2024 ASCO Annual Meeting
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL).
First Author: Stephen J. Freedland
Poster
2024 ASCO Genitourinary Cancers Symposium
Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK.
First Author: Stephen J. Freedland
Poster
2024 ASCO Genitourinary Cancers Symposium
Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2.
First Author: Karim Fizazi